key: cord-0896852-pky0vu7l
authors: Fu, Yiqi; Yang, Qing; Xu, Min; Kong, Haishen; Chen, Hongchao; Fu, Yajie; Yao, Yake; Zhou, Hua; Zhou, Jianying
title: Secondary bacterial infections in critical ill patients of COVID-19
date: 2020-06-05
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa220
sha: 0800b4e5d0a496b54ebb776cc0364ca16a55cd58
doc_id: 896852
cord_uid: pky0vu7l

Secondary bacterial infections occurred in 13.9% (5/36) of critical ill patients of COVID-19. All the five patients had been admitted to ICU and received mechanical ventilation before episode of bacterial infection. Active surveillance of culture should be performed for critical ill patients. Prevention of nosocomial infection needs to be taken seriously.

In December 2019, a new strain of coronavirus caused a pneumonia outbreak in Wuhan, Hubei province of China. Due to its ability to effectively transmit between humans, the novel virus, now named as SARS-CoV-2, has spread rapidly to the whole of China as well as other parts of the world. Secondary bacterial infection is an important complication of virus infection and associated with serious outcomes, especially in influenza [1] . Up to now, although several studies have investigated the epidemiological and clinical characteristics of COVID-19, information regarding secondary bacterial infection is limited [2, 3] . In present study, we report five cases of SARS-CoV-2 pneumonia complicated with secondary bacterial co-infection.

Zhijiang Medical Center is a newly built campus of The First Affiliated Hospital, College of Medicine, Zhejiang University in Hangzhou, Zhejiang Province, China. It was completed in October, 2019 and opened outpatient clinic since November, 2019 and then three internal medicine wards since January, 2020. After the outbreak of COVID-19, the campus is exclusively used for treatment of patients with SARS-CoV-2, including two newly opened medical intensive care units (MICU) with 29 beds each.

The microbiological and clinical data were retrospectively collected from electronic medical records. The definition of confirmed human infection with SARS-CoV-2 is in accordance with the WHO interim guidance [4] . The diagnosis of COVID-19 was confirmed by positive A c c e p t e d M a n u s c r i p t 5 result of real-time RT-PCR for respiratory specimens (rhinopharyngeal swab, sputum or bronchoalveolar lavage fluid).

Secondary bacterial co-infection was defined as positive bacterial cultures accompanied by corresponding clinical manifestations, such as fever/hypothermia, purulent respiratory secretions, new or progressive pulmonary infiltrates in chest radiograph and elevated peripheral white blood cell/C-reaction protein/procalcitonin. The data was de-identified, hence informed consent was waived. This study was approved by the Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University.

By February 29, 2020, 101 patients with confirmed COVID-19 were admitted to Zhijiang Medical Center including 36 patients in intensive care unit (ICU). 39 patients were subjected to microbial culture according to doctors' judgment. In total, five patients in ICU (5.0%, 5/101 for all patients; 13.9%, 5/36 for patients in ICU) were diagnosed as SARS-CoV-2 and secondary bacterial infection.

All the five patients were aged ≥55 years, hospitalized in ICU and received invasive mechanical ventilation (MV) before bacterial co-infection onset. Four were male with Charlson's comorbidity index ≥4. The average times from ICU admission and MV to bacterial co-infection onset were 11 days and 8.6 days, respectively ( Table S1 ). All of them were administered antibiotics before ( Figure 1 The timelines and clinical characteristics of the five cases were displayed in Figure 1 and Table S1 . 

In present study, we reported five cases of SARS-CoV-2 pneumonia complicated with secondary bacterial infection. The newly opened campus and ICU provided a special environment without colonization of common multidrug resistant nosocomial pathogens such as Acinetobacter baumannii, K. pneumoniae and Staphylococcus aureus. Thus, the present study provided relative true conditions of secondary bacterial infection in COVID-19, especially for critical ill patients in ICU.

The percentage of ICU patients was high in this study (35.6%, 36/101). The major cause was different tasks of hospitals during the outbreak of COVID-19 in Zhejiang Province. Our institution is the regional medical center of Zhejiang Province with advantages in infectious diseases and critical care medicine, and was designated as the special hospital for severe and critical ill patients. Thus, severe patients were transferred from other parts of Zhejiang Province and concentrated in our hospital.

Our results showed 5.0% (5/101) of all patients developed to bacterial co-infection, which was slightly higher than that reported by Chen et al (1%) [2] . It was believed that bacterial complications tended to present later in virus infection. The study of Chen et al [2] was conducted in the initial stage of the outbreak, so that was likely an underestimation of bacterial co-infection rate. Moreover, the occurrence of secondary bacterial infections is affected by the severity of COVID-19. In this study, all the five patients were critically ill in 

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: Interim guidance

Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States

Fatalities associated with the 2009 H1N1 influenza A virus in New York city

We thank all the doctors and medical staff fighting with COVID-19 in The First Affiliated Hospital, College of Medicine, Zhejiang University.

All authors report no potential conflicts of interest.

A c c e p t e d M a n u s c r i p t 11